AU2025203773A1 — Pharmaceutical composition for oral administration of edaravone and method of administering same

USPTO Abstract

Name of Document] Abstract To provide a pharmaceutical composition containing edaravone as an active ingredient for oral administration or equivalent administration. A pharmaceutical composition of the present invention is characterized by containing edaravone as an active ingredient, the pharmaceutical composition being administered to a subject orally or intragastrically with any one first time interval selected from the group consisting of 1) to 3) below: 1) in a case where the subject has consumed a high-fat meal, 8 hours or longer after the consumption; 2) in a case where the subject has consumed a standard meal, 4 hours or longer after the consumption; and 3) in a case where the subject has consumed a light meal, 2 hours or longer after the consumption.